Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination

Journal of Gene Medicine

Volumn 12, Issue 1, 2010, Pages 107-116

  Castellanos, Marlen ^a   Cinza, Zurina ^b   Dorta, Zaily ^a   Veliz, Gloria ^b   Vega, Héctor ^a   Lorenzo, Irma ^a   Ojeda, Sergio ^a   Dueñas Carrera, Santiago ^b   Alvarez Lajonchere, Liz ^b   Martínez, Gillian ^b   Ferrer, Elena ^a   Limonta, Miladys ^b   Linares, Marbelis ^b   Ruiz, Odalis ^b   Acevedo, Boris ^b   Torres, Dinorah ^b   Márquez, Gabriel ^b   Herrera, Luis ^b   Arús, Enrique ^a  

^a INSTITUTO DE GASTROENTEROLOGÍA   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Adverse event; Clinical trial; Hepatitis C; Plasmid; Transaminases

Indexed keywords

ALBUMIN; ALPHA INTERFERON; AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CIGB 230; CORE PROTEIN; DNA VACCINE; GLOBULIN; GLYCOPROTEIN E1; HEBERBIOVAC HB; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS C ANTIGEN; HEPATITIS C VACCINE; HIGH DENSITY LIPOPROTEIN; RIBAVIRIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VIRUS RNA;

ABSCESS; ADULT; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASTHENIA; ASTHMA; BILIRUBIN BLOOD LEVEL; BLOOD CHEMISTRY; BLOOD PRESSURE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DNA IMMUNIZATION; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ERYTHEMA; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MITOGENESIS; MYALGIA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RASH; SIDE EFFECT; SKIN INDURATION; SKIN INFILTRATE; SKIN PRURITUS; T LYMPHOCYTE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VOMITING;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODY FORMATION; CELL PROLIFERATION; EPITOPES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY; MALE; MIDDLE AGED; MITOGENS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 75449095840     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1407     Document Type: Article

References (47)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.
2. Almasio PL, Cottone C, D'Angelo F. Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment. Dig Liver Dis 2007; 39: S88-S95.
3. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 2007; 6: 991-1000.
4. Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med 2006; 45: 183-191.
5. Lechmann M, Liang TJ. Vaccine development for hepatitis C. Semin Liver Dis 2000; 20: 211-226.
6. Mikkelsen M, Bukh J. Current status of a hepatitis C vaccine: Encouraging results but significant challenges ahead. Curr Infect Dis Rep 2007; 9: 94-101.
7. Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003; 38: 1289-1296.
8. Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006; 24: 4343-4353.
9. Schlaphoff V, Klade CS, Jilma B, et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007; 25: 6793-6806.
10. Haller AA, Lauer GM, King TH, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and core proteins. Vaccine 2007; 25: 1452-1463.
11. Yutani S, Yamada A, Yoshida K, et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 2007; 25: 7429-7435.
12. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open-label trial of therapeutic immunization with oral V-5 immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine 2008; 26: 2733-2737.
13. Fields BN, Knipe DM. Fundamental Virology. Raven Press: New York, NY, 1996.
14. Acosta-Rivero N, Poutou J, Mussachio A, et al. Interaction of a C-terminal truncated hepatitis C virus core protein with plasmid DNA vaccine leads to in vitro assembly of heterogeneous virus-like particles. Am J Infect Dis 2005; 1: 66-72.
15. Alvarez-Lajonchere L, González M, Alvarez-Obregón JC, et al. Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice. Biotechnol Appl Biochem 2006; 44: 9-17.
16. Acosta-Rivero N, Aguilera Y, Falcon V, et al. Ultrastructural and immunological characterization of hepatitis C core protein-DNA plasmid complexes. Am J Immunol 2006; 2: 67-72.
17. Dueñas-Carrera S. DNA vaccination against hepatitis C. Curr Op Mol Ther 2004; 6: 146-150.
18. Dueñas-Carrera S, Alvarez-Lajonchere L, Alvarez-Obregón JC, et al. Enhancement of the immune response generated against the hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem 2002; 35: 205-212.
19. Acosta-Rivero N, Rodriguez A, Mussachio A, et al. A C-terminal truncated hepatitis C virus core protein variant assembles in vitro into virus-like particles in the absence of structured nucleic acids. Biochem Biophys Res Commun 2005; 334: 901-906.
20. Limonta M,Marquez G, Rey I, et al. Plasmid DNA recovery using size-exclusion and perfusion chromatography. Biopharm Int 2008; 21: 38-48.
21. Dueñas-Carrera S, Morales J, Acosta-Rivero N, et al. Variable level expression of hepatitis C virus core protein in a prokaryotic system. Analysis of the humoral response in rabbit. Biotecnol Apl 1999; 16: 226-231.
22. Rodríguez L, Balmaseda A, Bravo J, et al. Validación de un ultramicroELISA de detección de anticuerpos contra el antígeno de superficie de la hepatitis B. Rev Cubana Med Trop 1996; 48: 45-49.
23. Islam D, Lindberg AA, Christensson B. Peripheral blood cell preparation influences the level of expression of leukocyte cell surface markers as assessed with quantitative multicolor flow cytometry. Cytometry 1995; 22: 128-134.
24. Leroux-Roels G. Development of prophylactic and therapeutic vaccines against hepatitis C virus. Expert Rev Vaccines 2005; 4: 351-371.
25. Stauber RE, Stadlbauer V. Novel approaches for therapy of chronic hepatitis C. J Clin Virol 2006; 36: 87-94.
26. Glenting J, Wessels S. Ensuring safety of DNA vaccines. Microb Cell Fact 2005; 4: 26.
27. Gilbert SC, Moorthy VS, Andrews L, et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006; 24: 4554-4561.
28. Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62: 5845-5852.
29. Song BJ, Rohit KK. Update on side-effects from common vaccines. Immunol Allergy Clin North Am 2003; 23: 589-603.
30. Alvarez-Lajonchere L, Shoukry NH, Grá B, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009; 16: 156-167.
31. Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 2008; 28: 9-16.
32. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006; 41: 17-27.
33. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S.
34. Ramos-Casals M, Jara LJ, Medina F, et al. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med 2005; 257: 549-557.
35. Klinman DM, Takeno M, Ichino M, et al. DNA vaccines: Safety and efficacy issues. Springer Semin Immunopathol 1997; 19: 245-256.
36. Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgönne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2006; 2: 45-53.
37. PuotiC, Bellis L, GalossiA, et al. Antiviral treatment of HCV carriers with persistently normal ALT levels. Mini Rev Med Chem 2008; 8: 150-152.
38. Puoti C. Hepatitis C virus with normal transaminase levels. Dig Dis 2007; 25: 277-278.
39. Lukens JR, Cruise MW, Lassen MG, Hahn YS. Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol 2008; 180: 4875-4884.
40. Waggoner SN, Hall CH, Hahn YS. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol 2007; 82: 1407-1419.
41. Yao ZQ, Eisen-Vandervelde A, Waggoner SN, Cale EM, Hahn YS. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J Virol 2004; 78: 6409-6419.
42. Sarobe P, Jáuregui JI, Lasarte JJ, et al. Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. J Hepatol 1996; 25: 1-9.
43. Leroux-Roels G, Alvarado Esquivel C, DeLeys R, et al. Lymphoproliferative responses to hepatitis C virus core, E1, E2 and NS3 in patients with chronic hepatitis C infection treated with interferon alpha. Hepatology 1996; 23: 8-16.
44. Buxton JA, Kim JH. Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: a review of the evidence and current recommendations. Can J Infect Dis Med Microbiol 2008; 19: 197-202.
45. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42: 219-232.
46. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine 2008; 26: 6225-6231.
47. Frelin L, Alheim M, Chen A, et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4 A inhibit NS3/4A-expressing tumours in vivo. Gene Ther 2003; 10: 686-699.